COVID19 - Trivoice PLUS - Astra-Zeneca derde dosis, Vaccinatie tegen covid-19 bij kankerpatiënten: booster prik BNT161b2 vaccin na volledige vaccinatie met ChAdOx1-S vaccin (Tri-VOICE plus).
Opvolging van SARS-CoV-2 specifieke immuniteit na COVID-19 vaccinatie in bewoners en medewerkers van woonzorgcentra
PANFLUVAC: Universele bescherming tegenover epidemische en pandemische H3N2 influenzavirussen bij mens en varken door vaccinatie met heterovariante stammen
PANFLUVAC: Universele bescherming tegenover epidemische en pandemische H3N2 influenzaziekten bij mens en varken door vaccinatie met heterovariante stammen
Determinants of vaccination and willingness to vaccinate against COVID-19 among pregnant and postpartum women during the third wave of the pandemic: A European multinational cross-sectional survey
Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study
Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRPtiT vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy
Vaccine hesitancy for the COVID-19 vaccine booster dose among nursing home staff fully vaccinated with the primary vaccination course in Belgium
ENHANCING THE T-CELLS STIMULATORY CAPACITY OF HUMAN ANTIGEN PRESENTING CELLS AND THEIR USE IN VACCINATION
Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
Data from: Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium